Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangfei Yishen Granules (YFYSR) is a Traditional Chinese Medicine (TCM) botanical formula specifically developed for the treatment of stable Chronic Obstructive Pulmonary Disease (COPD). The formulation is based on the TCM principle of "nourishing the lungs and benefiting the kidneys" to address deficiency patterns common in chronic respiratory conditions. It is composed of several medicinal herbs, including *Astragalus membranaceus*, *Panax ginseng*, *Cornus officinalis*, and *Epimedium brevicornu*. Research indicates that YFYSR exerts anti-inflammatory and immunomodulatory effects, potentially by regulating the Th17/Treg cell balance and reducing the expression of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-8. Clinical trials have demonstrated its efficacy in reducing the frequency and severity of acute exacerbations, improving lung function (FEV1), and enhancing the quality of life for patients with COPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yangfei yishen granules.